OTCMKTS:SEOVF Sernova Biotherapeutics Q1 2026 Earnings Results & Report $0.08 +0.00 (+5.18%) As of 11:20 AM Eastern Sernova Biotherapeutics missed analyst earnings expectations in its Q1 2026 results, released March 19, 2026. The company reported EPS of -$0.01 versus the -$0.0073 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ1 2026Report DateMarch 19, 2026TimeAfter Market Closes Sernova Biotherapeutics EPS ResultsActual EPS-$0.01Consensus EPS -$0.0073Beat/MissMissed by -$0.0027One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersSernova Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSernova Biotherapeutics' next earnings date is estimated for Thursday, December 17, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sernova Biotherapeutics Q1 2026 Earnings FAQ Did Sernova Biotherapeutics beat earnings estimates for Q1 2026? Sernova Biotherapeutics (OTCMKTS:SEOVF) reported earnings of -$0.01 per share for Q1 2026, missing the consensus estimate of -$0.0073. The report was announced on Thursday, March 19, 2026. When is Sernova Biotherapeutics' next earnings date? Sernova Biotherapeutics' next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sernova Biotherapeutics on the company's earnings history page. Sernova Biotherapeutics Earnings HeadlinesSeraxis Names Former FDA Medical Officer Patricia Beaston As Chief Medical Officer Ahead Of MergerOctober 19, 2026 | rttnews.comSeraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova BiotherapeuticsOctober 19, 2026 | markets.businessinsider.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical TrialOctober 5, 2026 | globenewswire.comSernova Biotherapeutics Inc (SVA)September 25, 2026 | ca.investing.comSernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity ConferenceSeptember 25, 2026 | globenewswire.comSee More Sernova Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email. Email Address About Sernova BiotherapeuticsSernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical-stage biotechnology company developing regenerative medicine technologies intended to treat chronic diseases by replacing or supplementing missing or dysfunctional cells. The company’s primary platform is the Cell Pouch System, an implantable device designed to create a vascularized environment that can house therapeutic cells and release biologically active substances into the body. Sernova has focused its research and development activities on cell-based treatments for conditions including insulin-dependent diabetes, hemophilia A and hypothyroidism. Its diabetes program has involved implanting insulin-producing islet cells in the Cell Pouch, with the goal of restoring glucose-responsive insulin production. The company has also evaluated the platform for the delivery of factor VIII-producing cells for hemophilia A and thyroid hormone-producing cells for hypothyroidism. Founded in Canada, Sernova has conducted development activities and clinical collaborations in both Canada and the United States, including work with academic and medical research institutions. Its programs remain investigational, and the company’s technologies are subject to clinical, regulatory and manufacturing requirements before they can become broadly available treatments.View Sernova Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
